Vidaza is recommended for European licence
This article was originally published in Scrip
Executive Summary
Celgene's Vidaza (5-azacitidine), a first-in-class DNA demethylating agent, has been given a positive opinion by the EU's CHMPfor the treatment of myelodysplastic syndromes and acute myeloid leukaemia in adults who are not eligible for haematopoietic stem-cell transplantation.